Hussman Strategic Advisors Inc. Takes $2.83 Million Position in DexCom, Inc. $DXCM

Hussman Strategic Advisors Inc. purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 42,000 shares of the medical device company’s stock, valued at approximately $2,826,000.

Several other institutional investors have also bought and sold shares of the company. Andra AP fonden purchased a new stake in DexCom in the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. raised its holdings in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in shares of DexCom during the 3rd quarter valued at $29,000. Finally, Sound Income Strategies LLC increased its position in shares of DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.4%

DXCM stock opened at $73.67 on Wednesday. The company has a market capitalization of $28.73 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The company’s 50 day moving average price is $66.98 and its two-hundred day moving average price is $70.91.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm earned $0.45 EPS. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on DXCM shares. JPMorgan Chase & Co. decreased their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, October 31st. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and issued a $82.00 price target (down previously from $94.00) on shares of DexCom in a report on Monday, November 3rd. Stifel Nicolaus began coverage on DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target for the company. Finally, UBS Group decreased their price objective on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.30.

Insider Buying and Selling at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares in the company, valued at $2,071,946.40. This represents a 7.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 7,866 shares of company stock worth $448,177. 0.32% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.